1. Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019 (REPLACECOVID)
- Author
-
Jordana B. Cohen, MD, MSCE, Thomas C. Hanff, MD, MPH, University of Arizona, Department of Medicine, Hospital Nacional Carlos Alberto Seguín Escobedo, Arequipa, Peru, Department of Nephrology, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru, Hypertension Unit, Department of Pathology, Hospital Español de Mendoza, National University of Cuyo, IMBECU-CONICET, Mendoza, Argentina, Division of Nephrology, Stanford University School of Medicine, Stanford, CA, USA, Division of Infectious Diseases, University of Ottawa and The Ottawa Hospital Research Institute, Ottawa, ON, Canada, Unidad de VIH, Hospital Civil de Guadalajara and Universidad de Guadalajara, Guadalajara, Mexico, Universidad Católica de Buenos Aires, Buenos Aires, Argentina, Departamento de Medicina Interna, Hospital Obrero number 3 Caja Nacional de Salud, Santa Cruz de la Sierra, Bolivia, Departamento de Medicina, Hospital Alberto Barton Thompson, Callao, Peru, Department of Clinical Sciences, Danderyd University Hospital, Karolinska Institutet, Stockholm, Sweden, Division of Cardiology, University of Miami Miller School of Medicine, Miami, FL, USA, Departamento de Emergencia, Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru, Division of Cardiology, Department of Medicine, Hospital Español, Buenos Aires, Argentina, Division of Cardiovascular Medicine, University of Michigan Medical School, Ann Arbor, MI, USA, Jesse Chittams, MS, Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, NC, USA, Charles R Vasquez, MD, and Julio A. Chirinos, Associate Professor of Medicine at the Hospital of the University of Pennsylvania
- Published
- 2021